Level Biotechnology Inc. (TPEX:3118)
Taiwan
· Delayed Price · Currency is TWD 33.25
0.00 (0.00%)
At close: Mar 10, 2026
Level Biotechnology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 736.59 | 731.35 | 660.61 | 593.01 | 677.28 | Upgrade
|
| Revenue Growth (YoY) | 0.72% | 10.71% | 11.40% | -12.44% | 0.71% | Upgrade
|
| Cost of Revenue | 478.9 | 494.22 | 441.07 | 390.42 | 444.78 | Upgrade
|
| Gross Profit | 257.7 | 237.13 | 219.55 | 202.59 | 232.5 | Upgrade
|
| Selling, General & Admin | 160.48 | 148.92 | 137.98 | 123.66 | 138.52 | Upgrade
|
| Research & Development | 13.7 | 12.95 | 13.77 | 14.03 | 15.02 | Upgrade
|
| Operating Expenses | 174.15 | 161.81 | 151.99 | 137.69 | 153.54 | Upgrade
|
| Operating Income | 83.55 | 75.32 | 67.55 | 64.9 | 78.96 | Upgrade
|
| Interest Expense | -0.2 | -0.28 | -0.33 | -0.35 | -0.38 | Upgrade
|
| Interest & Investment Income | 3.42 | 5.45 | 5.18 | 2.47 | 1.67 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -1.2 | 0.01 | -1.17 | 1.65 | Upgrade
|
| Other Non Operating Income (Expenses) | 10.81 | 1.82 | 6.14 | 7.21 | 3.12 | Upgrade
|
| EBT Excluding Unusual Items | 97.58 | 81.1 | 78.55 | 73.07 | 85.02 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.02 | 0.1 | 0.08 | -0.13 | Upgrade
|
| Pretax Income | 97.58 | 81.13 | 78.65 | 73.16 | 84.89 | Upgrade
|
| Income Tax Expense | 17.88 | 16.31 | 15.75 | 14.69 | 16.71 | Upgrade
|
| Net Income | 79.7 | 64.81 | 62.91 | 58.47 | 68.18 | Upgrade
|
| Net Income to Common | 79.7 | 64.81 | 62.91 | 58.47 | 68.18 | Upgrade
|
| Net Income Growth | 22.97% | 3.03% | 7.59% | -14.25% | 17.46% | Upgrade
|
| Shares Outstanding (Basic) | 32 | 32 | 32 | 32 | 32 | Upgrade
|
| Shares Outstanding (Diluted) | 33 | 33 | 33 | 33 | 33 | Upgrade
|
| Shares Change (YoY) | 0.04% | -0.02% | -0.04% | 0.01% | 0.19% | Upgrade
|
| EPS (Basic) | 2.46 | 2.00 | 1.94 | 1.80 | 2.10 | Upgrade
|
| EPS (Diluted) | 2.44 | 1.99 | 1.93 | 1.79 | 2.09 | Upgrade
|
| EPS Growth | 22.61% | 3.11% | 7.82% | -14.35% | 17.42% | Upgrade
|
| Free Cash Flow | 26.94 | -159.58 | 62.54 | 58.33 | 146.8 | Upgrade
|
| Free Cash Flow Per Share | 0.82 | -4.89 | 1.92 | 1.79 | 4.49 | Upgrade
|
| Dividend Per Share | - | 1.800 | 1.700 | 1.700 | 1.900 | Upgrade
|
| Dividend Growth | - | 5.88% | - | -10.53% | 18.75% | Upgrade
|
| Gross Margin | 34.98% | 32.42% | 33.23% | 34.16% | 34.33% | Upgrade
|
| Operating Margin | 11.34% | 10.30% | 10.23% | 10.95% | 11.66% | Upgrade
|
| Profit Margin | 10.82% | 8.86% | 9.52% | 9.86% | 10.07% | Upgrade
|
| Free Cash Flow Margin | 3.66% | -21.82% | 9.47% | 9.84% | 21.67% | Upgrade
|
| EBITDA | 106 | 91.02 | 83.21 | 80.73 | 95.15 | Upgrade
|
| EBITDA Margin | 14.39% | 12.45% | 12.60% | 13.61% | 14.05% | Upgrade
|
| D&A For EBITDA | 22.46 | 15.7 | 15.65 | 15.82 | 16.19 | Upgrade
|
| EBIT | 83.55 | 75.32 | 67.55 | 64.9 | 78.96 | Upgrade
|
| EBIT Margin | 11.34% | 10.30% | 10.23% | 10.95% | 11.66% | Upgrade
|
| Effective Tax Rate | 18.32% | 20.11% | 20.02% | 20.08% | 19.69% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.